- Home
- WINA vs TSHA Comparison
WINA vs TSHA Comparison
Compare WINA & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINA
- TSHA
- Stock Information
- Founded
- WINA 1988
- TSHA 2019
- Country
- WINA United States
- TSHA United States
- Employees
- WINA N/A
- TSHA N/A
- Industry
- WINA Other Specialty Stores
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- WINA Consumer Discretionary
- TSHA Health Care
- Exchange
- WINA Nasdaq
- TSHA Nasdaq
- Market Cap
- WINA 1.4B
- TSHA 1.4B
- IPO Year
- WINA 1993
- TSHA 2020
- Fundamental
- Price
- WINA $403.17
- TSHA $4.96
- Analyst Decision
- WINA
- TSHA Strong Buy
- Analyst Count
- WINA 0
- TSHA 9
- Target Price
- WINA N/A
- TSHA $10.00
- AVG Volume (30 Days)
- WINA 77.9K
- TSHA 4.3M
- Earning Date
- WINA 10-15-2025
- TSHA 11-04-2025
- Dividend Yield
- WINA 2.81%
- TSHA N/A
- EPS Growth
- WINA 2.56
- TSHA N/A
- EPS
- WINA 11.21
- TSHA N/A
- Revenue
- WINA $84,517,400.00
- TSHA $8,098,000.00
- Revenue This Year
- WINA $7.05
- TSHA N/A
- Revenue Next Year
- WINA $3.60
- TSHA N/A
- P/E Ratio
- WINA $35.96
- TSHA N/A
- Revenue Growth
- WINA 3.35
- TSHA N/A
- 52 Week Low
- WINA $295.79
- TSHA $1.05
- 52 Week High
- WINA $527.37
- TSHA $5.51
- Technical
- Relative Strength Index (RSI)
- WINA 35.46
- TSHA 59.36
- Support Level
- WINA $383.24
- TSHA $4.70
- Resistance Level
- WINA $435.62
- TSHA $5.25
- Average True Range (ATR)
- WINA 18.71
- TSHA 0.37
- MACD
- WINA -3.74
- TSHA -0.07
- Stochastic Oscillator
- WINA 24.67
- TSHA 49.16
About WINA Winmark Corporation
Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment including Franchising and one non-reportable segment Leasing. The franchising segment franchises value-oriented retail store that buys, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.